Fig. 2

Cisplatin resistant models display increased activation of p90RSK pathway. (A) Table indicating top hits in drug sensitivities of HN30-R8 cells relative to HN30 cell. (B) Western blots of indicated cell lines after treatment with cisplatin for p-MEK, p-ERK, and p-p90RSK. One representative blot is shown. (C) Western blots of HN31 cells with induced overexpression of different p90RSK isoforms. One representative blot is shown. For B and C, fold changes of band intensities for respective protein are placed above the blot. (D) Viability of HN31 cells with overexpressing p90RSK isoforms treated with indicated concentrations of cisplatin. Comparisons are made between each p90RSK isoform to the wild type (W118∆) within each cisplatin treatment group. Statistical significance was calculated using two-way ANOVA with Dunnett’s multiple comparison test. *p < 0.05, **p 0.001, ***p < 0.0001